Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin Combined With Cisplatin and Concurrent Radiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07697040Phase 1Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jul 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of becotatug vedotin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoints: Maximum Tolerated Dose at 21 days, Recommended Phase 2 Dose at 21 days and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07697040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07697040.